Immunomic Therapeutics, Inc., (ITI) is a clinical stage biotechnology company with a novel technology called LAMP-vax for application to vaccines and vaccine immunotherapies. LAMP-vax promises to increase the effectiveness of the immune response to DNA vaccines while simplifying overall vaccine design and delivery. The technology is ideally suited for application to allergy immunotherapy.
CEO and Chairman
William G. Hearl, Ph.D.